izokibep
Jump to navigation
Jump to search
Indications
- investigational agent for treatment of psoriatic arthritis
Dosage
- injection
- 160 mg of weekly or biweekly
- 80 mg dose every 4 weeks
Mechanism of action
- IL-17A inhibitor
More general terms
References
- ↑ Gever J Izokibep Marches on for Psoriatic Arthritis.
Early phase III data cement case for novel IL-17A inhibitor. MedPage Today June 16, 2024 https://www.medpagetoday.com/meetingcoverage/eular/110670